Subsequent studies have also readily identified BRAFV600E mutations in PLGA (28, 30, 32, 37???39, 46, 47), although as discussed below these are most common in tumors other than PA.BRAF and RAF1 fusions are generally mutually exclusive with other genetic alterations activating MAPK signaling, but some exceptions to this have been reported.